[Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica]

Francisco Gudiol; José María Aguado; Alvaro Pascual; Miquel Pujol; Benito Almirante; José María Miró; Emilia Cercenado; María de Los Angeles Domínguez; Alex Soriano; Jesús Rodríguez-Baño; Jordi Vallés; Mercedes Palomar; Pilar Tornos; Emilio Bouza; Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica

doi:10.1016/j.eimc.2008.09.003

[Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica]

Enferm Infecc Microbiol Clin. 2009 Feb;27(2):105-15. doi: 10.1016/j.eimc.2008.09.003. Epub 2009 Feb 11.

[Article in Spanish]

Authors

Francisco Gudiol¹, José María Aguado, Alvaro Pascual, Miquel Pujol, Benito Almirante, José María Miró, Emilia Cercenado, María de Los Angeles Domínguez, Alex Soriano, Jesús Rodríguez-Baño, Jordi Vallés, Mercedes Palomar, Pilar Tornos, Emilio Bouza; Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica

Affiliation

¹ Servicio de Enfermedades Infecciosas, IDIBELL, Hospital Universitario de Bellvitge, Barcelona, España.

PMID: 19254641
DOI: 10.1016/j.eimc.2008.09.003

Abstract

Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA) are prevalent and clinically important. The rise in MRSA bacteremia and endocarditis is related with the increasing use of venous catheters and other vascular procedures. Glycopeptides have been the reference drugs for treating these infections. Unfortunately their activity is not completely satisfactory, particularly against MRSA strains with MICs > 1 microg/mL. The development of new antibiotics, such as linezolid and daptomycin, and the promise of future compounds (dalvabancin, ceftobiprole and telavancin) may change the expectatives in this field.The principal aim of this consensus document was to formulate several recommendations to improve the outcome of MRSA bacteremia and endocarditis, based on the latest reported scientific evidence. This document specifically analyzes the approach for three clinical situations: venous catheter-related bacteremia, persistent bacteremia, and infective endocarditis due to MRSA.

Publication types

Consensus Development Conference
English Abstract
Practice Guideline
Review

MeSH terms

Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use*
Bacteremia / drug therapy*
Bacteremia / etiology
Bacteremia / microbiology
Catheterization / adverse effects
Catheterization, Central Venous / adverse effects
Clinical Trials as Topic
Device Removal
Drug Resistance, Multiple, Bacterial
Early Diagnosis
Endocarditis, Bacterial / drug therapy*
Endocarditis, Bacterial / etiology
Endocarditis, Bacterial / microbiology
Endocarditis, Bacterial / surgery
Equipment Contamination
Evidence-Based Medicine
Heart Valve Prosthesis / adverse effects
Heart Valve Prosthesis Implantation
Humans
Methicillin Resistance
Methicillin-Resistant Staphylococcus aureus / drug effects
Methicillin-Resistant Staphylococcus aureus / isolation & purification*
Microbial Sensitivity Tests
Prevalence
Prospective Studies
Prosthesis-Related Infections
Staphylococcal Infections / drug therapy*
Staphylococcal Infections / etiology
Staphylococcal Infections / microbiology
Staphylococcal Infections / surgery
Vancomycin / therapeutic use

Substances

Anti-Bacterial Agents
Vancomycin